Akili (AKLI) Change In Receivables : $-0.26 Mil (TTM As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Akili Change In Receivables?

Akili's change in receivables for the quarter that ended in Dec. 2023 was $0.14 Mil. It means Akili's Accounts Receivable declined by $0.14 Mil from Sep. 2023 to Dec. 2023 .

Akili's change in receivables for the fiscal year that ended in Dec. 2023 was $-0.26 Mil. It means Akili's Accounts Receivable increased by $0.26 Mil from Dec. 2022 to Dec. 2023 .

Akili's Accounts Receivable for the quarter that ended in Dec. 2023 was $0.30 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Akili's Days Sales Outstanding for the three months ended in Dec. 2023 was 36.55.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Akili's liquidation value for the three months ended in Dec. 2023 was $53.52 Mil.

Akili Change In Receivables Historical Data

The historical data trend for Akili's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akili Change In Receivables Chart

Akili Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

-0.01

-0.02

-0.01

-0.26

Akili Quarterly Data
	Dec19	Sep20	Dec20	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Receivables	Get a 7-Day Free Trial								-0.01	-0.01	-0.04	-0.36	0.14

Akili Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.26 Mil.

Akili (NAS:AKLI) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Akili's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.3	/	0.749	*	91
=	36.55

2. In Ben Graham's calculation of liquidation value, Akili's accounts receivable are only considered to be worth 75% of book value:

Akili's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	75.15	-	21.851	+	0.75 * 0.3	+	0.5 * 0
=	53.52

Akili Change In Receivables Related Terms

Thank you for viewing the detailed overview of Akili's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Akili (AKLI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Akili Inc (NAS:AKLI) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

AKLI:Mexico

Address

125 Broad Street, Fifth Floor, Boston, MA, USA, 02110

Website

https://www.akiliinteractive.com

Akili Inc is a digital medicine company pioneering the development of cognitive treatments through game-changing technologies.

Executives

Jacqueline Studer	officer: Chief Legal Officer	IDEXX LABORATORIES, ONE IDEXX DRIVE, WESTBROOK ME 04092
Matthew Franklin	officer: See Remarks	AKILI INTERACTIVE LABS, INC., 125 BROAD STREET, 5TH FLOOR, BOSTON MA 02110
Martucci Walter Edward Ii	director, officer: Chief Executive Officer	AKILI INTERACTIVE LABS, INC., 125 BROAD STREET 5TH FLOOR, BOSTON MA 02110
Santosh Shanbhag	officer: Chief Financial Officer	AKILI INTERACTIVE LABS, INC., 125 BROAD STREET 5TH FLOOR, BOSTON MA 02110
Chamath Palihapitiya	director, 10 percent owner	THE SOCIAL-CAPITAL PARTNERSHIP, L.L.C., 506 SANTA CRUZ AVENUE, SUITE 300, MENLO PARK CA 94025
Mary Hentges	director	C/O SHOTSPOTTER, INC., 7979 GATEWAY BLVD., STE. 210, NEWARK CA 94560
Tls Beta Pte. Ltd.	10 percent owner	60B ORCHARD ROAD #06-18, THE ATRIUM@ORCHARD, SINGAPORE U0 238891
Temasek Holdings (private) Ltd	10 percent owner	60B ORCHARD ROAD #06-18 TOWER 2, THE ATRIUM@ORCHARD, SINGAPORE U0 238891
Fullerton Management Pte Ltd	10 percent owner	60B ORCHARD ROAD #06-18 TOWER 2, THE ATRIUM@ORCHARD, SINGAPORE U0 238891
Anil Jina	officer: Chief Medical Officer	AKILI INTERACTIVE LABS, INC., 125 BROAD STREET 5TH FLOOR, BOSTON MA 02110
Temasek Life Sciences Private Ltd	10 percent owner	60B ORCHARD ROAD #06-18, THE ATRIUM@ORCHARD, SINGAPORE U0 238891
Jonathan David	officer: Chief Product Officer	AKILI INTERACTIVE LABS, INC., 125 BROAD STREET 5TH FLOOR, BOSTON MA 02110
Kenneth Ehlert	director	AKILI INTERACTIVE LABS, INC., 125 BROAD STREET, 5TH FLOOR, BOSTON MA 02110
Christine Lemke	director	AKILI INTERACTIVE LABS, INC., 125 BROAD STREET, 5TH FLOOR, BOSTON MA 02110
Adam Gazzaley	director	AKILI INTERACTIVE LABS, INC., 125 BROAD STREET, 5TH FLOOR, BOSTON MA 02110